Allogene Therapeutics, Inc. (ALLO) SEC Filing 8-K Material Event for the period ending Thursday, June 10, 2021

Allogene Therapeutics, Inc.

CIK: 1737287 Ticker: ALLO

View differences made from one to another to evaluate Allogene Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Allogene Therapeutics, Inc..


Assess how Allogene Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Allogene Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Ticker: ALLO
CIK: 1737287
Form Type: 8-K Corporate News
Accession Number: 0001737287-21-000030
Submitted to the SEC: Tue Jun 15 2021 4:01:46 PM EST
Accepted by the SEC: Tue Jun 15 2021
Period: Thursday, June 10, 2021
Industry: Biological Products No Disgnostic Substances
  1. Financial Exhibit
  2. Vote of Security Holders

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: